RAVULIZUMAB

RAVULIZUMAB (12895Q)

ravulizumab 300 mg/3 mL injection, 3 mL vial
12895Q
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Grandfather (transition from non-PBS-subsidised treatment)

Restriction

Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: First Continuing Treatment

Restriction

Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Subsequent Continuing Treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 2 DPMQ: $6,623.00 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Ultomiris